Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts

D. H. Brown, B. J.M. Braakhuis, G. A.M.S. Van Dongen, M. Van Walsum, M. Bagnay, G. B. Snow

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In a previous study we established a markedly increased antitumour activity of 10-ethyl, 10-deaza-aminopterin (10-EdAM) as compared to methotrexate (MTX) when tested in vitro in squamous cell carcinoma cell lines from the head and neck (HNSCC). In this paper we describe the antitumour activity of these drugs in vivo in athymic nude mice bearing HNSCC xenografts. Using a schedule of 125 mg/kg i.p. for both drugs, injected on day 0 and 7, 10-EdAM caused a significant response in 2 out of 5 tumour lines, whereas MTX was completely inactive. These two lines moderately sensitive to 10-EdAM were not affected when the drug was given daily times 5 at an equitoxic dose of 0.75 mg/kg, indicating that the effect of the drug may be schedule dependent.

Original languageEnglish
Pages (from-to)1549-1552
Number of pages4
JournalAnticancer Research
Volume9
Issue number6
Publication statusPublished - 1 Dec 1989

Cite this

Brown, D. H. ; Braakhuis, B. J.M. ; Van Dongen, G. A.M.S. ; Van Walsum, M. ; Bagnay, M. ; Snow, G. B. / Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts. In: Anticancer Research. 1989 ; Vol. 9, No. 6. pp. 1549-1552.
@article{6bd0ab96f05141159db4dcdef9bb1d2f,
title = "Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts",
abstract = "In a previous study we established a markedly increased antitumour activity of 10-ethyl, 10-deaza-aminopterin (10-EdAM) as compared to methotrexate (MTX) when tested in vitro in squamous cell carcinoma cell lines from the head and neck (HNSCC). In this paper we describe the antitumour activity of these drugs in vivo in athymic nude mice bearing HNSCC xenografts. Using a schedule of 125 mg/kg i.p. for both drugs, injected on day 0 and 7, 10-EdAM caused a significant response in 2 out of 5 tumour lines, whereas MTX was completely inactive. These two lines moderately sensitive to 10-EdAM were not affected when the drug was given daily times 5 at an equitoxic dose of 0.75 mg/kg, indicating that the effect of the drug may be schedule dependent.",
keywords = "10-EdAM, antifolates, head and neck cancer, methotrexate, xenografts",
author = "Brown, {D. H.} and Braakhuis, {B. J.M.} and {Van Dongen}, {G. A.M.S.} and {Van Walsum}, M. and M. Bagnay and Snow, {G. B.}",
year = "1989",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "1549--1552",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

Brown, DH, Braakhuis, BJM, Van Dongen, GAMS, Van Walsum, M, Bagnay, M & Snow, GB 1989, 'Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts' Anticancer Research, vol. 9, no. 6, pp. 1549-1552.

Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts. / Brown, D. H.; Braakhuis, B. J.M.; Van Dongen, G. A.M.S.; Van Walsum, M.; Bagnay, M.; Snow, G. B.

In: Anticancer Research, Vol. 9, No. 6, 01.12.1989, p. 1549-1552.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against human head and neck cancer xenografts

AU - Brown, D. H.

AU - Braakhuis, B. J.M.

AU - Van Dongen, G. A.M.S.

AU - Van Walsum, M.

AU - Bagnay, M.

AU - Snow, G. B.

PY - 1989/12/1

Y1 - 1989/12/1

N2 - In a previous study we established a markedly increased antitumour activity of 10-ethyl, 10-deaza-aminopterin (10-EdAM) as compared to methotrexate (MTX) when tested in vitro in squamous cell carcinoma cell lines from the head and neck (HNSCC). In this paper we describe the antitumour activity of these drugs in vivo in athymic nude mice bearing HNSCC xenografts. Using a schedule of 125 mg/kg i.p. for both drugs, injected on day 0 and 7, 10-EdAM caused a significant response in 2 out of 5 tumour lines, whereas MTX was completely inactive. These two lines moderately sensitive to 10-EdAM were not affected when the drug was given daily times 5 at an equitoxic dose of 0.75 mg/kg, indicating that the effect of the drug may be schedule dependent.

AB - In a previous study we established a markedly increased antitumour activity of 10-ethyl, 10-deaza-aminopterin (10-EdAM) as compared to methotrexate (MTX) when tested in vitro in squamous cell carcinoma cell lines from the head and neck (HNSCC). In this paper we describe the antitumour activity of these drugs in vivo in athymic nude mice bearing HNSCC xenografts. Using a schedule of 125 mg/kg i.p. for both drugs, injected on day 0 and 7, 10-EdAM caused a significant response in 2 out of 5 tumour lines, whereas MTX was completely inactive. These two lines moderately sensitive to 10-EdAM were not affected when the drug was given daily times 5 at an equitoxic dose of 0.75 mg/kg, indicating that the effect of the drug may be schedule dependent.

KW - 10-EdAM

KW - antifolates

KW - head and neck cancer

KW - methotrexate

KW - xenografts

UR - http://www.scopus.com/inward/record.url?scp=0024826385&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1549

EP - 1552

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -